Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 297

1.
2.

Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.

Rabien A, Burkhardt M, Jung M, Fritzsche F, Ringsdorf M, Schicktanz H, Loening SA, Kristiansen G, Jung K.

Eur Urol. 2007 May;51(5):1259-66. Epub 2006 Jun 14.

PMID:
16806661
3.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
6.

Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.

Zhou M, Hayasaka S, Taylor JM, Shah R, Proverbs-Singh T, Manley S, Rubin MA.

J Urol. 2001 Dec;166(6):2193-7.

PMID:
11696734
7.

The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression.

Madigan MC, Kingsley EA, Cozzi PJ, Delprado WJ, Russell PJ, Li Y.

Cancer Immunol Immunother. 2008 Sep;57(9):1367-79. doi: 10.1007/s00262-008-0473-x. Epub 2008 Feb 14.

PMID:
18273614
8.
9.

L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer.

Koutalellis G, Stravodimos K, Avgeris M, Mavridis K, Scorilas A, Lazaris A, Constantinides C.

BJU Int. 2012 Sep;110(6 Pt B):E267-73. doi: 10.1111/j.1464-410X.2012.11152.x. Epub 2012 May 9.

11.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

12.
14.

Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer.

Ploussard G, Salomon L, Allory Y, Terry S, Vordos D, Hoznek A, Abbou CC, Vacherot F, de la Taille A.

BJU Int. 2010 Jul;106(1):86-90. doi: 10.1111/j.1464-410X.2009.09080.x. Epub 2009 Nov 20.

15.
16.
17.

Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.

Steuber T, Budäus L, Walz J, Zorn KC, Schlomm T, Chun F, Ahyai S, Fisch M, Sauter G, Huland H, Graefen M, Haese A.

BJU Int. 2011 Jun;107(11):1755-61. doi: 10.1111/j.1464-410X.2010.09730.x. Epub 2010 Oct 13.

18.

Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.

Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.

J Urol. 2005 Dec;174(6):2181-5.

PMID:
16280760
19.

Expression and clinical significance of CD147 in genitourinary carcinomas.

Han ZD, He HC, Bi XC, Qin WJ, Dai QS, Zou J, Ye YK, Liang YX, Zeng GH, Zhu G, Chen ZN, Zhong WD.

J Surg Res. 2010 May 15;160(2):260-7. doi: 10.1016/j.jss.2008.11.838. Epub 2008 Dec 10.

PMID:
19286191
20.

Quantification of PSA mRNA levels in peripheral blood of patients with localized prostate adenocarcinoma before, during, and after radical prostatectomy by quantitative real-time PCR (qRT-PCR).

Kalfazade N, Kuskucu AM, Karadag S, Sahin S, Aras B, Midilli K, Yilmaz G, Tasci AI.

Int Urol Nephrol. 2009;41(2):273-9. doi: 10.1007/s11255-008-9416-x. Epub 2008 Jun 27.

PMID:
18584300

Supplemental Content

Support Center